Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Leonard S. Schleifer, M.D., Ph.D., Regeneron's president and chief executive officer, will provide an overview of the company and its clinical programs. His presentation is scheduled to be broadcast live on Wednesday, May 2, 2007 at 3:00 pm Eastern Time. The session may be accessed through the Company's website (www.regeneron.com on the Events page, under the Investor Relations heading) at the time of the presentation. An archived version of the presentation will be available shortly after the live webcast and be accessible through June 1, 2007.
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders.
Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com.
SOURCE: Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. Investors: Charles Poole, 914-345-7640 Investor.relations@regeneron.com or Media: Lauren Tortorete, 212-845-5609 ltortorete@biosector2.com